| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
381,510,000 |
| Market
Cap: |
169.20(M) |
| Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,595 |
| 52
Week Range: |
$0.4435 - $2.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
500,000 |
525,000 |
525,000 |
| Total Buy Value |
$0 |
$324,050 |
$343,050 |
$343,050 |
| Total People Bought |
0 |
1 |
2 |
2 |
| Total Buy Transactions |
0 |
1 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Armen Garo H |
Chairman & CEO |
• – – |
2010-04-26 |
4 |
A |
$1.19 |
$9,917 |
D/D |
8,334 |
1,618,674 |
|
- |
|
| Armen Garo H |
CEO |
• – – |
2010-04-01 |
4 |
A |
$0.76 |
$11,009 |
D/D |
14,485 |
1,610,340 |
|
- |
|
| Valentine Karen |
VP and General Counsel |
• – – |
2010-03-16 |
4 |
S |
$0.76 |
$22,006 |
D/D |
(29,039) |
51,491 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2010-03-11 |
4 |
S |
$0.79 |
$69,007 |
D/D |
(87,628) |
1,595,855 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2010-03-10 |
4 |
A |
$0.77 |
$178,316 |
D/D |
231,579 |
1,683,483 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2010-03-01 |
4 |
A |
$0.78 |
$11,000 |
D/D |
14,122 |
1,451,904 |
|
- |
|
| Armen Garo H |
CEO |
• – – |
2010-02-01 |
4 |
A |
$0.79 |
$10,999 |
D/D |
13,932 |
1,437,782 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2010-01-20 |
4/A |
AS |
$0.85 |
$54,488 |
D/D |
(63,848) |
237,068 |
|
- |
|
| Wentworth Kerry |
VP, Clin, Reg & Quality |
• – – |
2010-01-20 |
4/A |
AS |
$0.85 |
$87,316 |
D/D |
(102,316) |
140,537 |
|
- |
|
| Klaskin Christine M |
VP Finance |
• – – |
2010-01-20 |
4/A |
AS |
$0.85 |
$67,306 |
D/D |
(78,868) |
69,488 |
|
- |
|
| Valentine Karen |
VP and General Counsel |
• – – |
2010-01-20 |
4/A |
AS |
$0.85 |
$80,040 |
D/D |
(93,789) |
80,530 |
|
- |
|
| Wentworth Kerry |
VP, Clin, Reg & Quality |
• – – |
2010-01-20 |
4 |
S |
$0.85 |
$87,316 |
D/D |
(102,316) |
140,537 |
|
- |
|
| Valentine Karen |
VP and General Counsel |
• – – |
2010-01-20 |
4 |
S |
$0.85 |
$80,040 |
D/D |
(93,789) |
80,530 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2010-01-20 |
4 |
S |
$0.85 |
$54,488 |
D/D |
(63,848) |
237,068 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2010-01-20 |
4 |
S |
$0.85 |
$67,306 |
D/D |
(78,868) |
69,488 |
|
- |
|
| Wentworth Kerry |
VP, Clin, Reg & Quality |
• – – |
2010-01-19 |
4 |
A |
$0.90 |
$122,779 |
D/D |
136,421 |
242,853 |
|
- |
|
| Valentine Karen |
VP and General Counsel |
• – – |
2010-01-19 |
4 |
A |
$0.90 |
$84,410 |
D/D |
93,789 |
174,319 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2010-01-19 |
4 |
A |
$0.90 |
$122,779 |
D/D |
136,421 |
300,916 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2010-01-19 |
4 |
A |
$0.90 |
$70,981 |
D/D |
78,868 |
148,356 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2010-01-01 |
4 |
A |
$0.71 |
$10,999 |
D/D |
15,453 |
1,423,850 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2009-12-01 |
4 |
A |
$0.94 |
$10,999 |
D/D |
11,720 |
1,408,397 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2009-11-02 |
4 |
A |
$1.74 |
$11,000 |
D/D |
6,320 |
1,396,677 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2009-10-01 |
4 |
A |
$2.12 |
$10,998 |
D/D |
5,182 |
1,375,357 |
|
- |
|
| Valentine Karen |
VP and General Counsel |
• – – |
2009-09-11 |
4 |
S |
$2.32 |
$2,541 |
D/D |
(1,094) |
80,530 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2009-09-11 |
4 |
S |
$2.32 |
$3,078 |
D/D |
(1,325) |
69,488 |
|
- |
|
535 Records found
|
|
Page 17 of 22 |
|
|
